top of page

SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC

SWOG S2012 - Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung


CLINICALTRIALS.GOV IDENTIFIER: NCT05058651


DRUG/TREATMENT: Atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) 


PHASE: II/III


STATUS: Recruiting


SPONSOR: National Cancer Institute (NCI)



Dr. David Zhen Discusses SWOG S2012 Immunotherapy (atezolizumab)



DESCRIPTION:

This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). 


The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. 


Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone. 


For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here.


CONTACT: This is a multicenter trial with various locations. Go to the “Contacts and Locations” section of this trial page at ClinicalTrials.gov for site-specific contact information. 


Principal Investigator:

David B. Zhen, MD

Southwest Oncology Group


bottom of page